Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020Initiated efficacy phase of NIH-funded EnACT study of MAT2203 […]